3SBio Inc. Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer
SHENYANG, China, Jan. 9, 2017 /PRNewswire/ -- 3SBio Inc., (HKEX:1530) ("3SBio" and together with its subsidiaries the "3SBio Group") is pleased to announce thatZhenping Zhu, MD, PhD, has joined 3SBio as its new President of Research & Development and Chief Scientific Officer. "We are pleased to ...
3SBio Inc. Selected as a Constituent of the MSCI China Index
SHENYANG, China, May 13, 2016 /PRNewswire/ -- 3SBio Inc., (HKEX:1530) ("3SBio") today announced that according to an announcement posted on the MSCI Inc. website onMay 12, 2016, 3SBio will be added as a constituent to the MSCI China Index after the market closes onMay 31, 2016. "We are pleased ...
3SBio's PEG-irinotecan Wins IND Approval From China FDA
SHENYANG, China, March 7, 2016 /PRNewswire/ -- 3SBio Inc., ("3SBio") a leading biotechnology company based inChina focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has received an Investigational New Drug ("IND") approval letter ...
3SBio Inc. Announces Expansion of its Leadership Team
SHENYANG, China, March 4, 2016 /PRNewswire/ -- 3SBio Inc. (Hong Kong: 1530) ("3SBio" and together with its subsidiaries the "3SBio Group") is pleased to announce thatKevin Xiao Weihong has joined 3SBio as its new chief operating officer. "We are pleased to welcome Kevin to 3SBio where he will p...
3SBio Signs Exclusive Patent License Agreement for ALT-P7, an Antibody-drug Conjugate Targeting HER2 with Alteogen
SHENYANG, China, and DAEJEON, Korea, Oct. 12, 2015 /PRNewswire/ -- 3SBio Inc. ("3SBio") (01530.HK), a leadingChina-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive licensing dea...
3SBio Inc. Selected as a Constituent of the Hang Seng Composite LargeCap & MidCap Index
SHENYANG, China, Aug. 17, 2015 /PRNewswire/ -- 3SBio Inc., (HKEX: 1530) ("3SBio") today announced that effectiveSeptember 14, 2015, it will be added as a constituent of the Hang Seng LargeCap & MidCap Index according to a press release issued by Hang Seng Indexes Company Limited ("Hang Seng") o...
3SBio Acquires Zhejiang Wansheng Pharmaceutical
SHENYANG, China, July 24, 2015 /PRNewswire/ -- - Adds integrated small molecule drug R&D and manufacturing platform - Expands product offering for chronic kidney disease and oncology patients - Further addresses unmet medical needs in diabetes-related complications and dermatology - Increas...
3SBio Acquires Global Rights to Anti-TNF mAb
SHENYANG, China, June 22, 2015 /PRNewswire/ -- 3SBio Inc., (HKEX: 1530) ("3SBio"), a leadingChina-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the ex-China global rights to Apexigen's ...
